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normalized absorbed doses (%) MOSFET film 
mean 95.0 96.4 
standard dev. 5.4 5.0 
u (MSE) 1.4 1.3 
2u (2 MSE) 2.8 2.6 
Table 1. Descriptive statistics of the in vivo data 
 
 Fig. 1. 
The uncertainty given for a single measurement based solely on 
detector and linac factors is greater and leads to a more conservative 
AL, whereas the AL derived from the MSE accounts for the variability 
involved in the whole procedure. 
Conclusions: An AL could be established after a thorough evaluation 
of the uncertainties associated with the in vivo dosimetry method 
employed. When added to the intended absorbed doses interval, this 
leads to non-action intervals (e.g. 85%-105% or 87%-103%, from our 
data and examples). As seen, these AL would remain coherent with in 
vivo dosimetry breast results already published and could be an initial 
proposal for future intervention protocols. 
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Purpose/Objective: Breast conserving therapy with complementary 
radiotherapy is an effective alternative for mastectomy; randomized 
trials in 20-years observations confirmed the comparable survivals in 
women treated with BCT and mastectomy. Standard procedure after 
BCT is whole breast irradiation (which reduces local risk of recurrence 
in about 16-30%) with higher dose on tumour bed (it decreases the risk 
of recurrence by 6%) for 5-7 weeks. The dose escalation may be 
proceeded by interstitial and cavital brachytherapy, intraoperative 
radiotherapy and conformal RT (3D-CRT) from external beams.  
In this study IORT was the only method used to boost the tumour bed. 
The aim of the study was to evaluate effectiveness of treatment, 
analyse early and late radiation reactions, cosmetic effect and quality 
of patients life.  
Materials and Methods: There were analysed 150 patients after BCT, 
IORT (10Gy/1 fraction; electron beam) and EBRT (50Gy/25 fractions; 
two tangential photon beams) with minimal observation period of 1 
year. The clinical profile is presented in table below. 
 
Tab.1  
Tumour size Number of 
pts. 
Tis 9 
T1mi 1 
T1a 1 
T1b 45 
T1c 79 
T2 15 
T3 0 
T4 0 
Histopatology Number of pts.
ductal invasive 71 
lobular invasive 2 
ductal invasive+DCIS 52 
lobular invasive+LCIS 1 
DCIS 8 
LCIS 0 
mucinous, apocrinal, tubular 16 
Patients number with feature N+: 25. 
 
During observation after IORTand in 1st, 6th, 12th, 24th and 36th 
month after EBRT we made: 
l physical examination,  
l photos of the breast,  
l analysis of acute and late toxicity.  
Patients filled in the quality of live questionnaires (QLQ-C30 and QLQ-
BR23) with the same frequency as observation schedule. 
Six months after EBRT mammography with ultrasounds of the breast 
was made in all patients.  
Results: No local recurrence occurred during observation period. 
Acute skin reactions in grade 1 and 2 were observed in 21,2% of 
patients, although therewere no acute and late toxicities both in 
grade 3 and 4. The cosmetic outcome according to the physical 
examination and photos analysis was good to excellent in 81,5% of 
patients. Pain in breast was observed in 20,6 % patients and 
hyperesthesia of the skin in 17,0 % patients. 
The edema of breast was reported by 81,3 % of patients after 1 
month, 63,4% after 6 months, 54,9 % after 1 year and 56% after 2 
years fromend of RT. The colour of breast skin has changed in 67,8 % 
of patients after 1 month, 44,1 % after 6 months, 37,8 % after 1 year, 
31% after 2 years from the end of RT. 
Conclusions: There was no local recurrences. IORT with EBRT was 
well tolerated, with no severe acute and late toxicities of the skin. 
The external beam course afterwards was shortenedby 1 week. After 
tumor resection the tumor bed can be precisely covered by the 
homogenous electron beam with no geographical mistake.  
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Purpose/Objective: Two randomized trials (Eliot; Targit) are showing 
encouraging data in favour of breast IORT in the field of partial breast 
irradiation. We present a new breast applicator to optimize the dose 
delivery with IORT using 50 kV X ray brachytherapy (XRB). 
Materials and Methods: In order to mimic the mamosite ® and 
intrabeam® applicator we developed an applicator to achieve the 
following characteristics: homogeneous dose at the surface of a 
spheric volume; protection of the skin overlying the surgical incision; 
good fixation and coaptation of the breast tissues of the tumor bed to 
the applicator; possible shielding of some tissues at risk (chest wall, 
lung); short treatment time and easy radioprotection. Between 2010 
and 2012 a series of dummy spherical applicators were tested with 
two breast surgeons to create the optimal sizes, shapes, fixation and 
shielding devices. A series of hollow nylon made applicators were then 
produced using a rapid prototyping procedure. These applicators were 
tested in sham irradiation with patients using the Papillon system 
(Ariane Medical systems™) delivering 50 kVp X-Rays. The dose 
distribution was measured and calculated with ion chamber, 
gafchromic films and a dedicated TPS with Monte Carlo algorythm 
(MC2Plan®). An international patent was given to the NBA. 
Results: Applicators between 3 and 6 cm diameter were tested 
(figure). The dose uniformity was excellent (± 4%) at the surface of 
the 310 ° spherical NBA (the isotropic X Ray source being in the center 
of the NBA). The percentage depth dose was in average (depending on 
the diameter of the NBA) 60% (of the surface dose) at 5 mm and 40% 
at 1cm. The eyelet positioned on the rim of the NBA made the fixation 
stable and the rim with the 310° beam resulted in a good protection 
of the overlying skin on the 'north pole' of the NBA. Thanks to forced 
cooling of the X ray tube anode, the Papillon system ® can deliver a 
typical 20 Gy treatment in 2 to 3 minutes. A flexible lead apron 
positioned at the surface of the patient during treatment made the 
radioprotection simple (medical and paramedical staff can stay in the 
OR during irradiation behind screen if needed). The first clinical 
results will be presented at the time of the meeting. 
Conclusions: The NBA used with the Papillon system provides a good 
dose distribution into the breast tumor bed after local excision. The 
easy and accurate positioning by the surgeon, the very short 
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treatment time and simple radioprotection measures should position 
this new medical device as an interesting alternative for breast IORT.  
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Purpose/Objective: To analyze prognostic factors associated with 
survival in patients after intensified radio-surgical rescue of 
oligorecurrent pelvic cancer, particularly the influence of external 
beam radiation therapy (EBRT).  
Materials and Methods: From January 1995 to december 2011, 81 
patients [colorectal (46%); gynecologic (26%); retroperitoneal sarcoma 
(18%)] underwent extended surgery [multiorgan (58%), bone (23%), 
vascular (9%), soft tissue (43%)] and intraoperative electron-beam 
radiation therapy [IOERT (10-15 Gy)] to the pelvic recurrence tumor 
bed. 35 (43%) of these patients also received EBRT (30.6-50.4 Gy). 
Survival outcomes were estimated using the Kaplan-Meier method, 
and risk factors were identified by univariate and multivariate 
analyses.  
Results: Median follow-up was 34 months (3-189 months), and the 1- 
3-, and 5-year rates of locoregional control (LRC) were 83%, 53%, and 
41%, respectively. Univariate Cox proportional hazard analysis 
revealed worse LRC for those patients who did not received integrated 
EBRT treatment for the pelvic recurrence rescue (p=0.003), and had 
non-radical resection (p=0.01). On multivariate analysis, integrated 
EBRT treatment, non-radical resection, and tumor fragmentation 
retained significance (p=0.002,p=0.004, and p=0.05, respectively).  
Conclusions: EBRT treatment integrated for rescue, radical resection, 
and abscence of tumor fragmentation are associated with improved 
LRC in patients with oligorecurrent pelvic cancer. Present results 
suggest that patients with oligorecurrent pelvic disease ma ybenefit 
from EBRT treatment integrated with extended surgery and IOERT. 
   
OC-0481   
External-beam radiation therapy, surgery and intraoperative 
electrons for locally recurent rectal cancer 
F. Calvo1, C.V. Sole1, P. Alvarez de Sierra2, M. Gomez-Espi1, J. 
Blanco1, M.A. Lozano1, E. del Valle3, M. Rodriguez3, A. Muñoz-Calero4, 
F. Turegano4 
1Hospital Gregorio Marañón, Radiation Oncology, Madrid, Spain  
2Hospital Gregorio Marañón, General Surgery III, Madrid, Spain  
3Hospital Gregorio Marañón, General Surgery I, Madrid, Spain  
4Hospital Gregorio Marañón, General Surgery II, Madrid, Spain  
 
Purpose/Objective: To analyze prognostic factors associated with 
survival in patients after intraoperative electrons containing resective 
surgical rescue of locally recurrent rectal cancer (LRRC), particularly 
the influence of an integrated component of external beam radiation 
therapy (EBRT).  
Materials and Methods: From January 1995 to december 2011, 60 
patients with pelvic recurrence from rectal inicial cancer primaries 
underwent extended surgery [n=38; multiorgan(43%), bone (28%), soft 
tissue (38%)] or non-extended (n=22) surgical resection, including a 
component of intraoperative electron-beam radiation therapy (IOERT) 
to the pelvic recurrence tumor bed. Twenty-eight (47%) of these 
patients were amenable and also received EBRT (range, 30.6-50.4 Gy). 
Survival outcomes were estimated using the Kaplan-Meier method, 
and risk factors were identified by univariate and multivariate 
analyses.  
Results: Median follow-up was 36 months (range, 2-189), the 1- 3-, 
and 5-year rates of LRC were 86%, 52%, and 44%, respectively. On 
univariate analysis, patients with R1 resection (5-year LRC=55.7% vs. 
19.0%, p=0.02) and not receiving EBRT (5-year LRC= 56.2% vs. 32.0%, 
p=0.02) were at a significantly higher risk of LR recurrence. Patients 
without tumor fragmentation, non-metastasic lymph nodes, abscence 
of perineural invasion and age > 55 had a lower risk of LRrelapse. We 
observed on multivariate analysis that margin status (R1resection), 
EBRT at the time of pelvic recurrence, no tumor fragmentation and 
non-lymph node metastasis retained significance with regard to LR 
relapse.  
Conclusions: EBRT treatment integrated for rescue, resection 
radicality, and not involved fragmented resection specimens are 
associated with improved LRC in patients with locally recurrent rectal 
cancer. Additionaly tumor fragmentation could be compensated by 
EBRT. Present results suggest that a significant group of patients with 
oligorecurrent pelvic disease may benefit from EBRT treatment 
integrated with extended surgery and IOERT. 
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Purpose/Objective: Patients with locally advanced rectal cancer are 
reported to have a dismal prognosis, challenging expert 
interdisciplinary manaegment. The purpose of this study is to analyze 
the 15-years results of neoadjuvant-based multimodality treatment 
for locally advanced rectal cancer (LARC) with particular emphasis on 
intraoperative electron-beam radiotherapy (IEORT). 
Materials and Methods: A total of 335 patients with LARC [≥cT3 93% 
and/or cN+ 69%) who underwent multimodality treatment between 
1995 and 2011 were studied. The basic treatment principle was 
preoperative(chemo)radiotherapy, intended radical surgery, IOERT 
and elective adjuvant chemotherapy (aCT). In uni- and multivariate 
analyses, risk factors for all loco-regional recurrence (LR), IOERT in-
field recurrence (IFR) and IOERT out-field recurrence (OFR) were 
studied. 
Results: Median follow-up for all patients was 52. 2 months (range, 1-
184), the 5 year overall survival, disease-free survival, local control, 
in-field and out-field control rates were 73.6%, 69.4%, 94.4%, 97.0% 
and 93.4%, respectively. Synchronic local and distant metastasic 
disease was present in 16% of the patients that recurred. In 
multivariate analysis distal margin distance < 20 mm [HR 3.74 (1.79-
7.82),p < 0.001], ypN+ [HR 2.53 (1.16-5.54), p = 0.02] and tumor 
histology grade 3[HR 7.0 (2.8-17.56), p < 0.001]; Non-sphincter 
preserving surgery [HR 6.49(1.58-26.32), p=0.009], cT4 [HR 6.24 (1.34-
29.1)], ypN+ [HR 7.41 (1.96-28.0)] and tumor histology grade 3 [HR 8.5 
(2.8.-27.44), p < 0.001]; gender [HR 2.87 (1.10-7.46), p = 0.03], distal 
margin distance < 20 mm [HR 4.37 (1.68-11.34), p = 0.002] and no aCT 
[HR 2.62(1-03-1.68), p = 0.04] were associated with increased risk of 
LR, IFR and OFR, respectively.  
Conclusions: Overall oncological results after multimodality 
treatment of LARC are promising. The positive impact of 
intraoperative radiotherapy on pelvic control does justify the inclusion 
of this therapeutic modality in prospective multi-institutional trials. 
Cancer death with uncontrolled pelvic progression was 28%. Adding 
aCT to the treatment may contribute to improve LR rates.  
   
OC-0483   
ISIORT-Europe Data Registry: main characteristics of IORT 
treatments 
M. Krengli1, F. Calvo2, F. Sedlmayer3, F. Wenz4, M. Litoborski5, C. 
Pisani1, A. Ciabattoni6, W. Polkowski7, A. Kuten8, J.B. Dubois9 
1University of Piemonte Orientale, Radiotherapy, Novara, Italy  
2University Hospital Gregorio Maranon, Radiotherapy, Madrid, Spain  
3University Of Salzburg, Radiotherapy, Salzburg, Austria  
4University Hospital Mannheim, Radiotherapy, Mannheim, Germany  
5Greater Poland Cancer Centre, Radiotherapy, Poznan, Poland  
6Hospital San Filippo Neri, Radiotherapy, Roma, Italy  
7University Hospital of Lublin, Radiotherapy, Lublin, Poland  
8Rambam Health Care Campus, Radiotherapy, Haifa, Israel  
9Cantre Régional de Lutte contre le Cancer Val d'Aurelle Montpellier, 
Radiotherapy, Montpellier, France  
 
